HDAC

HDAC

HDAC (Histone Deacetylases) are a group of enzymes that allow histones to more tightly wrap the DNA by removing acetyl groups (O=C-CH3) from -N-acetyl lysine amino acids. This is significant because DNA is wrapped around histones and that acetylation and de-acetylation control how DNA is expressed. In contrast to histone acetyltransferase, it acts differently. Since non-histone proteins are also among their targets, HDAC proteins are now also referred to as lysine deacetylases (KDAC) in order to better reflect their mode of action. The histone deacetylases are members of the ancient protein superfamily known as the histone deacetylase superfamily, along with the acetylpolyamine amidohydrolases and the acetoin utilization proteins.

HDAC related products

Structure Cat No. Product Name CAS No. Product Description
V55231 HL23 1448355-15-4 HL23 is a histone deacetylase (HDAC) inhibitor (antagonist) with anti-hepatocellular carcinoma (HCC) activity.
V52892 ITF 3756 2247608-27-9 ITF 3756 is a potent and specific HDAC6 inhibitor.
V2087 ITSA-1 200626-61-5 ITSA-1 is a novel, potent, cell-membrane permeable and specific HDAC (Histone deacetylase) activator that suppressesTSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.
V12132 KA2507 monohydrochloride 2972712-63-1 KA2507 HCl is a highly efficient and selective HDAC6 inhibitor (IC50=2.5 nM) without obvious toxicity.
V75845 KPZ560 2397562-43-3 KPZ560 is a potent inhibitor of HDAC1 and HDAC2 with IC50 of 12 nM and 68 nM respectively.
V55242 KT-531 2490284-18-7 KT-531 is a potent and specific inhibitor of HDAC6 with IC50 of 8.5 nM.
V55232 LW479 1688677-89-5 LW479 is a new HDAC inhibitor and is expected to be a candidate active molecule for the prevention of breast cancer.
V53365 MOCPAC 787549-26-2 MOCPAC is an HDAC1-specific substrate.
V41169 MPT0G211 2151853-97-1 MPT0G211 is a potent, orally bioactive and selective HDAC6 inhibitor (IC50=0.291 nM).
V41170 MPT0G211 mesylate 2151854-33-8 MPT0G211 mesylate is a potent, orally bioactive and selective HDAC6 inhibitor (IC50=0.291 nM).
V25171 NKL 22 537034-15-4 NKL 22 (compound 4b) is a potent and specific histone deacetylase (HDAC) inhibitor (antagonist) with IC50s of 199 and 69 nM for HDAC1 and HDAC3, respectively.
V11393 NR-160 NR-160 is a novel, potent and selective HDAC6 (Histone Deacetylase 6) inhibitors with bifurcatedcapping groups.
V41097 NR160 2484895-50-1 NR160 is a selective HDAC6 inhibitor (antagonist) with IC50 of 30 nM.
V41088 NT160 1418293-40-9 NT160 is a potent class IIa HDAC inhibitor (antagonist) with IC50 of 0.046 μM.
V55235 PB131 2924425-63-6 PB131 is a selective, brain barrier-penetrating HDAC6 inhibitor (antagonist) with high binding affinity (IC50= 1.8 nM).
V13533 Quisinostat HCl 1083078-98-1 Quisinostat HCl (formerly JNJ-26481585; JNJ 26481585; JNJ26481585), the hydrochloride salt ofQuisinostat, is an orally bioavailable, 2nd generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antitumor activity.
V36625 SHP2/HDAC-IN-1 2831230-38-5 SHP2/HDAC-IN-1 is an allosteric dual SHP2/HDAC inhibitor (antagonist) with IC50s of 20.4 nM (SHP2) and 25.3 nM (HDAC1).
V32595 Sodium Butyrate 156-54-7 Sodium Butyrate, the sodium salt of butyrate, is ashort-chainfattyacid acting asan histone deacetylase (HDAC) inhibitor with anticancer activity.
V55229 SP-2-225 2364448-93-9 SP-2-225 is a selective HDAC6 inhibitor.
V3192 SR-4370 1816294-67-3 SR-4370 is an inhibitor ofHDAC (Histone deacetylases), withIC50values of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.
Contact Us Back to top